Zeroing in on resistance
Vienna – Austrian Nabriva Therapeutics AG has recruited 210 patients for a Phase II study with its antibiotic BC-3781, a substance for treating acute bacterial skin infections. In the study, Nabriva will compare response rates of a 100 mg and a 150 mg BC-3781 dose with the antibiotic vancomycin, the current standard of care. B-3781 is a first-in-class pleuromutilin that is intended to fight infections with multi-drug resistant pathogens like MRSA. Secondary endpoints include cessation of the spread of lesions within 72 hours and the resolution of fever.